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Abstract
Osteoclast precursors arise from the CD14+ CD16- population in
controls but details about cell surface marker expression and
functional characteristics of these cells is unknown, particularly in
patients with inflammatory arthritis. In a recent issue of Arthritis,
Research and Therapy, Lari and colleagues found that osteoclasts
developed from a proliferative CD14+ CD16- subset in healthy
controls. These cells took on the morphology of osteoclasts, ex-
pressed mRNA for osteoclast-related genes and excavated pits on
bone wafers. These findings provide new insights into monocyte
diversity and provide evidence that osteoclast precursors arise
from a small proliferating monocyte population in controls.
Additional studies are needed in patients with inflammatory arthritis
“…Since (these cells) aside from their capacity to
stretch out prolongations also are capable of
consuming foreign bodies, we will subsume them
under the joint name of fagocytes [sic]….”
Ellie Metchnikoff 1884
In a recent issue of Arthritis, Research and Therapy, Lari and
colleagues provide evidence that osteoclast precursors arise
from a novel subset of proliferating monocytes [1]. Research
in this area originated with the seminal observations of
Metchnikoff regarding the central importance of phagocytosis
to human physiology, which culminated in a Noble Prize and
laid the groundwork for the field of innate immunity at the
opening of the last century [2]. Macrophages, pivotal effector
cells in the innate immune response, maintain host defense,
but also participate in wound healing and immune regulation
[3]. In addition, precursor populations that differentiate into
tissue macrophages exhibit heterogeneity in terms of surface
marker expression and cytokine production [4]. Circulating
monocytes have been divided into classical monocytes,
which are CD14+ CD16-, and a small subset considered as
non-classical monocytes, which are CD14+ CD16+ [5]. This
latter population is increased in the circulation and synovial
tissues of rheumatoid arthritis patients and these cells display
an inflammatory phenotype characterized by increased
release of interleukin-1 and tumor necrosis factor following
exposure to lipopolysaccharide [6]. A unique subpopulation
of CD14+ CD16- cells that exhibit a proliferative phenotype
in vitro was identified by investigators in John Hamilton’s
laboratory and may represent an immature monocyte that has
the ability to replicate in target tissues [7].
Circulating monocytes exhibit remarkable plasticity, being
capable of differentiation into not only macrophages but also
dendritic cells or osteoclasts in response to specific environ-
mental signals [8]. Of particular interest is the finding that
osteoclast precursors (OCPs) are elevated in the circulation
of rheumatoid arthritis and psoriatic arthritis patients; in the
case of psoriatic arthritis, elevated numbers of these cells
correlate with joint damage and declined rapidly after patients
were treated with anti-tumor necrosis factor agents [9]. In
separate studies, OCPs were found to arise from the CD14+
CD16+ population [10].
Lari and colleagues [1] provide evidence that OCPs arise
from a proliferative monocyte subpopulation in healthy
controls. Previously, they reported that proliferative monocytic
cells that express CD14, c-Fms, CD64 and CD33 but not
CD16 give rise to osteoclasts in vitro based on an analysis of
three healthy controls [10]. In the recent study [1], they
analyzed monocytes from 13 healthy donors and demon-
strated that osteoclasts were derived from the proliferative
but not the non-proliferative fraction based on analysis of
carboxyfluorescein succinimidyl ester (CFSE)-labeled cells.
The authors state that functional analysis of proliferation may
provide a better tool for identification of specific monocyte
subsets since it is difficult to know if specific patterns of
surface marker expression represent different states of
activation or differentiation.
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The demonstration that OCPs derive from this proliferative
monocyte population in controls is intriguing but must be
interpreted with caution for several reasons. First, in vitro
studies of monocytes can yield markedly different results
depending on a variety of experimental variables, including
cell density, serum concentrations and labeling conditions. To
demonstrate the presence of this rare proliferative subset,
cells were cultured for 9 days after labeling with CSFE. The
expression data on osteoclast-related genes were obtained
on day 23 of culture and osteoclasts were counted on
day 30. The fact that culture artifacts may obscure in vivo
characteristics must be considered. Second, the cell surface
phenotype was based on analysis of only three subjects,
which weakens the premise that the parent population is
CD16- given the high variability between subjects in
expression of this marker. Lastly, it is highly likely that
systemic (elevated production of tumor necrosis factor) and
local (upregulation of RANKL (receptor activator for nuclear
factor κB ligand)) events in patients with inflammatory arthritis
dramatically alter the phenotype of circulating monocytes and
these features are unlikely to be present in controls. Thus,
alterations in monocyte populations obtained from healthy
subjects may be considerably different from those observed
in patients with inflammatory arthritis.
Despite these concerns, the importance of this proliferative
subset in rheumatoid and psoriatic arthritis should be
examined. If these proliferative monocytes prove to be
expanded in arthritis and are progenitors of osteoclasts, several
important questions need to be addressed. Are these
precursor cells committed to the osteoclast lineage or can they
differentiate into dendritic cells or macrophages? Are these
cells CD16- as observed in controls or CD16+ as reported in
psoriatic arthritis? Do they express higher levels of c-Fms on
the cell surface as a mechanism to account for the increased
proliferative capacity and lastly do they express unique cell
surface markers? This last point is particularly important
because the methods employed in these studies are not
feasible for detection of this population by clinical laboratories
due to the requirement for cell labeling and prolonged culture.
Increasing evidence points to a pivotal function for monocyte/
macrophages not only in synovial inflammation and joint
destruction but also in obesity, eye and bowel inflammation
and cardiovascular disease, which occur in many subjects
with psoriasis and psoriatic arthritis [11]. Thus, it is crucial to
understand if distinct monocyte precursor populations can
differentiate into specific monocyte effectors because they
may provide the much sought after susceptibility or response
biomarkers for a number of different inflammatory disorders.
The quest for these markers continues and this report high-
lights a novel population that may further clarify characteristic
features of this elusive precursor population.
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